CN104136442B - 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 - Google Patents
作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 Download PDFInfo
- Publication number
- CN104136442B CN104136442B CN201380010104.4A CN201380010104A CN104136442B CN 104136442 B CN104136442 B CN 104136442B CN 201380010104 A CN201380010104 A CN 201380010104A CN 104136442 B CN104136442 B CN 104136442B
- Authority
- CN
- China
- Prior art keywords
- och
- pain
- compound
- mmol
- isopropoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CSC*)c1ccn[n]1C Chemical compound CC(CSC*)c1ccn[n]1C 0.000 description 13
- VHUQQIRVKGGNAV-UHFFFAOYSA-N CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1(C1)OC(c2cc([I]=C)cnc2)=CC1=O)=O Chemical compound CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1(C1)OC(c2cc([I]=C)cnc2)=CC1=O)=O VHUQQIRVKGGNAV-UHFFFAOYSA-N 0.000 description 1
- YBJOLWGIMMRKGX-UHFFFAOYSA-N CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1=CC(CC(c1cc(F)cnc1)=O)=O)=O Chemical compound CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1=CC(CC(c1cc(F)cnc1)=O)=O)=O YBJOLWGIMMRKGX-UHFFFAOYSA-N 0.000 description 1
- RKDQHZMFDAKFJO-UHFFFAOYSA-N CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1=O)=O Chemical compound CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1=O)=O RKDQHZMFDAKFJO-UHFFFAOYSA-N 0.000 description 1
- YAGFEVPBUINWNC-UHFFFAOYSA-N CCNC(c(cc1C)ccc1OC(C)C)=O Chemical compound CCNC(c(cc1C)ccc1OC(C)C)=O YAGFEVPBUINWNC-UHFFFAOYSA-N 0.000 description 1
- PXJTVCUOJDSHPL-UHFFFAOYSA-N Cc([s]1)ncc1S1CC1 Chemical compound Cc([s]1)ncc1S1CC1 PXJTVCUOJDSHPL-UHFFFAOYSA-N 0.000 description 1
- LUHWCDODJOEFAD-UHFFFAOYSA-N Cc(nc(cc1Br)[Br]=C)c1O Chemical compound Cc(nc(cc1Br)[Br]=C)c1O LUHWCDODJOEFAD-UHFFFAOYSA-N 0.000 description 1
- NODLZCJDRXTSJO-UHFFFAOYSA-N Cc1n[n](C)cc1 Chemical compound Cc1n[n](C)cc1 NODLZCJDRXTSJO-UHFFFAOYSA-N 0.000 description 1
- ZENGVBCBQDANQQ-UHFFFAOYSA-N O=C(N(CC1)CCC1(C1)OC([AlH2])=CC1=O)[AlH2] Chemical compound O=C(N(CC1)CCC1(C1)OC([AlH2])=CC1=O)[AlH2] ZENGVBCBQDANQQ-UHFFFAOYSA-N 0.000 description 1
- IDMNMSDRXZBGEJ-UHFFFAOYSA-N O=C(N(CC1)CCC1=O)[AlH2] Chemical compound O=C(N(CC1)CCC1=O)[AlH2] IDMNMSDRXZBGEJ-UHFFFAOYSA-N 0.000 description 1
- DSJVDBQSMJIVIN-UHFFFAOYSA-N OC(C1)CC(CC2)(CCN2C([Ar])=O)OC1[AlH2] Chemical compound OC(C1)CC(CC2)(CCN2C([Ar])=O)OC1[AlH2] DSJVDBQSMJIVIN-UHFFFAOYSA-N 0.000 description 1
- XFELOOACGNFGLD-UHFFFAOYSA-N OC1C=C([AlH2])[U]C(CC2)(CCN2C([AlH2])=O)C1 Chemical compound OC1C=C([AlH2])[U]C(CC2)(CCN2C([AlH2])=O)C1 XFELOOACGNFGLD-UHFFFAOYSA-N 0.000 description 1
- APVVYEFGLIUECA-UHFFFAOYSA-N S=Cc1cnc[s]1 Chemical compound S=Cc1cnc[s]1 APVVYEFGLIUECA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586875P | 2012-01-16 | 2012-01-16 | |
| US61/586,875 | 2012-01-16 | ||
| PCT/US2013/021535 WO2013109521A1 (en) | 2012-01-16 | 2013-01-15 | Pyran-spirocyclic piperidine amides as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104136442A CN104136442A (zh) | 2014-11-05 |
| CN104136442B true CN104136442B (zh) | 2016-12-21 |
Family
ID=47595110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380010104.4A Expired - Fee Related CN104136442B (zh) | 2012-01-16 | 2013-01-15 | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9403839B2 (https=) |
| EP (1) | EP2804868B1 (https=) |
| JP (1) | JP6215230B2 (https=) |
| CN (1) | CN104136442B (https=) |
| AU (1) | AU2013209958B2 (https=) |
| CA (1) | CA2863343A1 (https=) |
| ES (1) | ES2631611T3 (https=) |
| MX (1) | MX2014008591A (https=) |
| NZ (1) | NZ627259A (https=) |
| WO (1) | WO2013109521A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| KR102731924B1 (ko) * | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| CN108276307A (zh) * | 2018-01-17 | 2018-07-13 | 常熟浸大科技有限公司 | 3-氰基-4-烃氧基苯甲酸酯的合成方法 |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060052597A1 (en) * | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| WO2010002483A1 (en) * | 2008-07-03 | 2010-01-07 | Cv Therapeutics, Inc. | Optionally condensed dihydro pyridine, dihydropyrimidine and dihydro pyrane derivatives acting as late sodium channel blockers |
| CN101910166A (zh) * | 2007-11-13 | 2010-12-08 | 沃泰克斯药物股份有限公司 | 用作钠离子通道调节剂的杂环衍生物 |
| CN102036985A (zh) * | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
| WO2012125613A1 (en) * | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US121652A (en) | 1871-12-05 | Improvement in picture-frame hangers | ||
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE69633245T2 (de) * | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
| US7576207B2 (en) * | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| WO2010151815A2 (en) * | 2009-06-25 | 2010-12-29 | Abbott Laboratories | 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof |
| WO2010151597A1 (en) * | 2009-06-26 | 2010-12-29 | Schering Corporation | Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers |
| JP5940562B2 (ja) * | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
-
2013
- 2013-01-15 JP JP2014552376A patent/JP6215230B2/ja active Active
- 2013-01-15 ES ES13700841T patent/ES2631611T3/es active Active
- 2013-01-15 AU AU2013209958A patent/AU2013209958B2/en not_active Expired - Fee Related
- 2013-01-15 MX MX2014008591A patent/MX2014008591A/es unknown
- 2013-01-15 EP EP13700841.3A patent/EP2804868B1/en active Active
- 2013-01-15 CN CN201380010104.4A patent/CN104136442B/zh not_active Expired - Fee Related
- 2013-01-15 NZ NZ627259A patent/NZ627259A/en not_active IP Right Cessation
- 2013-01-15 WO PCT/US2013/021535 patent/WO2013109521A1/en not_active Ceased
- 2013-01-15 CA CA2863343A patent/CA2863343A1/en not_active Abandoned
- 2013-01-15 US US14/372,353 patent/US9403839B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060052597A1 (en) * | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| CN101910166A (zh) * | 2007-11-13 | 2010-12-08 | 沃泰克斯药物股份有限公司 | 用作钠离子通道调节剂的杂环衍生物 |
| CN102036985A (zh) * | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
| WO2010002483A1 (en) * | 2008-07-03 | 2010-01-07 | Cv Therapeutics, Inc. | Optionally condensed dihydro pyridine, dihydropyrimidine and dihydro pyrane derivatives acting as late sodium channel blockers |
| WO2012125613A1 (en) * | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015505321A (ja) | 2015-02-19 |
| US20150005304A1 (en) | 2015-01-01 |
| JP6215230B2 (ja) | 2017-10-18 |
| CN104136442A (zh) | 2014-11-05 |
| EP2804868A1 (en) | 2014-11-26 |
| EP2804868B1 (en) | 2017-04-12 |
| AU2013209958B2 (en) | 2017-09-07 |
| CA2863343A1 (en) | 2013-07-25 |
| WO2013109521A1 (en) | 2013-07-25 |
| AU2013209958A1 (en) | 2014-08-07 |
| US9403839B2 (en) | 2016-08-02 |
| MX2014008591A (es) | 2014-08-22 |
| NZ627259A (en) | 2016-12-23 |
| ES2631611T3 (es) | 2017-09-01 |
| HK1203074A1 (zh) | 2015-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104136442B (zh) | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 | |
| EP2686325B1 (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels | |
| US9511067B2 (en) | Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels | |
| JP5940562B2 (ja) | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド | |
| US10233191B2 (en) | Fused piperidine amides as modulators of ion channels | |
| WO2014022639A1 (en) | Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone | |
| HK1203074B (en) | Pyran-spirocyclic piperidine amides as modulators of ion channels | |
| HK1191952A (en) | Chroman-spirocyclic piperidine amides as modulators of ion channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1203074 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1203074 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161221 Termination date: 20180115 |